Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Snapshot of some VERY long term Trogarzo users
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(214)
•••
Comment by scarlet1967on Feb 10, 2021 12:11pm
80 Views
Post# 32526004

RE:RE:Snapshot of some VERY long term Trogarzo users

RE:RE:Snapshot of some VERY long term Trogarzo usersIt is all about$$$$.

"Boris Johnson today froze ministerial pay in a stark signal on the need for public sector restraint amid the coronavirus meltdown.

The PM acted amid growing outrage over plans to hand MPs a £3,000 hike because their salaries are linked to the wider public sector - which has been seeing a surge in pay over the past year.

But fears are mounting about the precarious state of the government's finances, as it is on track to borrow more than £300billion this year due to the pandemic."

https://www.dailymail.co.uk/news/article-8835881/PM-sends-signal-need-public-sector-restraint-freezing-ministerial-pay.html
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities